One year round up – what we’ve been up to in our first year
The 1st September 2019 officially marks the one year anniversary of the launch of TherapeutAix – and what an exciting year it’s been! To celebrate the occasion, we’ve taken a look back at what the company has achieved so far. Company launch After months of preparation, we officially launched TherapeutAix on 1st September 2018 along […]
International NASH Day 2019
On International NASH Day 2019 we discuss the mixed outcomes of NASH drug clinical trials and how we believe a platform of evidence can be built to support future NASH drug development. NASH (Nonalcoholic steatohepatitis) is emerging as a major public health issue for the 21st century that affects 7-12% of adults worldwide. It is […]
TherapeutAix adds Immunoconsulting to global R&D Network
We are pleased to announce that we have grown our global R&D Network with the addition of ImmunoConsulting Ltd. ImmunoConsulting, a consulting business that provides assistance to pharmaceutical and academic spin-out companies developing new therapeutic strategies which target components of the immune system across all therapy areas, is the latest company to join our extensive […]
Recent study highlights the challenges in developing treatments for NASH
We previously commented on the failure of the ASK-1 inhibitor, selonsertib, in the STELLAR-4 phase III study in patients with compensated cirrhosis (F4) due to NASH. Selonsertib has been tested in another study (STELLAR-3) in an earlier stage (F3) of NASH, where it has now been announced that also here, selonsertib failed to meet the primary endpoint of […]
TherapeutAix/Medicines Discovery Catapult session on drug discovery in fibrotic disease at the BOS Basel event in Switzerland
BOS (Biotech Outsourcing Strategies) Basel 2019 will bring together stakeholders in pharmaceutical R&D outsourcing, who share knowledge, develop skills and build new and existing relationships with those in the field. The event will cover Drug Discovery Outsourcing and Development Stage CMC Outsourcing for both Small Molecules and Biologics. BOS Basel 2019 will take place on […]
TherapeutAix is speaking at the 18th Fraunhofer Seminar “Models of Lung Disease”
Darcey Black, Translational Director of TherapeutAix, will be speaking at the 18th Fraunhofer Seminar titled “Models of Lung Disease” on Friday 25th of January. Held in Hannover, Germany, the two-day event will bring together 120 academics and industry experts for discussions on predictive disease models and translational lung research. Darcey will give a presentation entitled […]
2018 Round Up – It’s a wrap
Since 2018 is quickly coming to an end, we look back at the past few months and reflect on all that we have achieved. The launch of the business is all wrapped up and now we look forward to what 2019 will bring. We would like to thank all of our clients and contacts for […]
Navigating the NASH Maze
The availability of 2 approved medicines for the treatment of idiopathic pulmonary fibrosis (IPF) has stimulated an explosion in fibrosis research and in the search for new anti-fibrotic agents. Nowhere is this more evident than in the field of non-alcoholic steatohepatitis (NASH). While there have been multiple review articles covering NASH of late, TherapeutAix is […]
TherapeutAix to present at ELRIG’s flagship conference, Drug Discovery
The European Laboratory Research & Innovation Group’s (ELRIG) flagship conference, Drug Discovery, is one of the largest meetings of life sciences industry professionals in the UK. Now in its 12th year, Drug Discovery 2018 will take place in London’s Excel Arena. The 2-day event will bring together more than 1200 delegates and over 100 exhibiting […]
TherapeutAix present at The Society for Medicines Research meeting
The Society for Medicines Research (SMR) is holding a meeting on 26th September 2018 in Stevenage titled, ‘The Best of Both Worlds: Innovation, Collaboration and Synergy between CROs and their Client Partners.’ The meeting will showcase innovation in science that has emerged from successful Client-CRO partnerships which have moved beyond fee-for-service agreements, towards much broader […]